Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 1,101–1,200 of 1,639
Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types
Alba, M. M., Lee, W. H., Lee, J. S. H., Lu, Z., Stiles, B. L., & Ligumsky, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-04097-4 · Cited by 4
“These effects have driven the widespread use of GLP-1-based therapies globally, and research continues to explore additional therapeutic uses [3, 8–11].”
Insuficiência Cardíaca no Brasil: Como Podemos Melhorar sua História Natural?
Ferrari, F., Rossi, A. P., & Santander, I. R. M. F. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240644 · Cited by 1
Lama, S., Chaudhuri, S., Blankenship, D. M., Ban, A. N., Usvyat, L. A., Pecoits-Filho, R., & Hippen, B. E. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101476 · Cited by 1
“15 An analysis of the STEP 1, 2, and 3 trials showed that lower (1.0 mg) doses of semaglutide resulted in significant reductions in hs-CRP levels, a finding independent of significant weight loss.”
InfluentialItaly passes obesity law: an opportunity to prevent cardiovascular disease across Europe
Malavazos, A. E., Dubini, C., Meregalli, C., Boniardi, F., Scravaglieri, V., Castelvecchio, S., Menicanti, L., Nisoli, E., & Carruba, M. O. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag094 · Cited by 1
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Kuo, Y.-J., Chen, L.-F., Chen, Y., Chen, P., & Lin, H. Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094120 · Cited by 3
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Dalal, N., Saxena, A., Mohsen, A., Borgi, J., Tatum, D. M., & Divya, A. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100565 · Cited by 1
Contractile effects of albiglutide in the human and mouse atrium
Jn, N., Jarikova, M., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1831742 · Cited by 1
Verelst, F. R., Witte, K. K., Ahmed, F. Z., Al‐Khatib, S. M., Parkash, R., Gevaert, A. B., & Spall, H. G. C. V. (2026) · Heart · doi:10.1136/heartjnl-2025-326954 · Cited by 1
“%) and obesity 55 (table 3).”
Self-citationEffects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
Heinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
“So konnten in diesem Kollektiv sowohl bei Personen mit (STEP-HFpEF DM) wie auch ohne T2D (STEP-HFpEF) Herzinsuffizi-enzsymptome signifikant reduziert werden [148, 149].”
Considerations Regarding Management of Heart Failure in Older Adults
Alagiakrishnan, K., Mah, D., Aronow, W. S., Lam, P. H., Frishman, W. H., Ahmed, A., & DEEDWANIA, P. C. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000677 · Cited by 1
Kim, B., Bae, S., Kim, S. J., Im, S. I., & Heo, J.-H. (2025) · Kosin Medical Journal · doi:10.7180/kmj.25.124 · Cited by 1
Integrative Lifestyle Intervention for Obesity-Related Diastolic Dysfunction
Arulalan, S. L., Lovell, T. T., Annie, F., et al. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104449 · Cited by 1
Leslie, A., Kovoor, J. J., & Bacchi, S. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.04.311 · Cited by 1
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
“A typical design would ran-domise such patients to GLP-1 RA or dual incretin therapy versus placebo on top of guideline-directed HF treatment, with a cardiovascular-driven primary endpoint [5, 24–26].”
InfluentialMedical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Velasco, M. Á. P., Trenas, A., Bernal-López, M. R., et al. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.12.017 · Cited by 1
Ibe, T., Demmer, R. T., Harada, T., Doi, S., Tada, A., Naser, J. A., Reddy, Y. N. V., & Borlaug, B. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3745 · Cited by 2
Self-citationEpicardial Adipose Tissue and Cardiac Dysfunction: Progress in knowledge but Questions Remain
Lobeek, M., Rienstra, M., & Gorter, T. M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3063 · Cited by 1
Semaglutide Exposure During Pregnancy: Results from the FAERS Database
Zinzi, A., Gaio, M., Mascolo, A., Pieretti, G., Cipriani, M., Ragione, J. M. D., D’Amato, R., Rossi, F., Capuano, A., & Ruggiero, R. (2026) · Pharmaceuticals · doi:10.3390/ph19081249 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“%) with semaglutide versus placebo (95% CI, 4.8 to 10.9; p < 0.001) [5].”
InfluentialAriyaratnam, J., Elliott, A. D., Mishima, R. S., Dziano, J. K., Emami, M., Howie, J. O., Middeldorp, M. E., & Sanders, P. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.08.011 · Cited by 5
Lin, X., Jiang, C., Wang, Z., Arima, H., Wang, X., Billot, L., Neal, B. C., Rodgers, A., Hillis, G. S., Patel, A. A., et al. (2025) · medRxiv · doi:10.1101/2025.06.19.25329849 · Cited by 1
Cardiovascular Science, Medicine, and Society: The Brave New World
Regan, J. A., Laitner, M. H., & Dzau, V. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.085 · Cited by 3
Post-prandial acyl ghrelin infusion in heart failure patients increases gastric emptying rate
Webb, D., Hage, C., Faxén, U. L., Pironti, G., Thorvaldsen, T., Andersson, D. C., Ståhlberg, M., Lund, L. H., & Hellström, P. M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05245-5 · Cited by 1
“This may have benefits against HFpEF Although the rapid GER group achieved the highest median score by the last time point, there were no significant differences (Kosiborod et al. 2023).”
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Tuttle, K. R., Kanbay, M., Alicic, R. Z., Carrero, J. J., Çöpür, S., Navar, A. M., Neuen, B. L., Perkovic, V., Rossing, P. R., Marx, N., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01117-6 · Cited by 4
Ahmad, B., Singh, P., Shah, R. J., Arif, M. H., Goel, A., Saeed, M., Saleh, A. O., Amer, S., Mukhlis, M., Waqas, S. A., et al. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102628 · Cited by 1
Fan, R., He, X., & Fan, Z. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02926-1 · Cited by 1
“Integrating these composite metabolic-imaging markers could facilitate the early identification of the CKM phenotype, prompting earlier initiation of therapies such as SGLT2 inhibitors or GLP-1 receptor agonists that target both metabolic control and cardiac remodeling [35].”
Nalbandian, M., Lone, J., Moal, E. L., Kim, I., Li, Y., Kraft, P., Zhao, M., Kolacar, K., Zhang, Z., Svensson, K. J., et al. (2026) · bioRxiv · doi:10.64898/2026.02.26.708119 · Cited by 1
“In addition to their metabolic effects, these agents offer cardioprotective (12) and renal benefits (13), which explains their growing appeal in treating obesity as a systemic disease.”
Obesity and Heart Failure: Introducing the Theme
Monitillo, F., Basile, P., & Lisco, G. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13040153 · Cited by 2
“Similar results were found in a population with obesity-related HFpEF, regardless of T2D, in which semaglutide 2.4 mg/weekly improves symptoms, attenuates physical limitations, and exercise tolerance and induces greater weight loss than placebo [125–127].”
InfluentialMallol-Simmonds, M., Avila, C., Cañete, I., Parra-Lucares, A., Pena-Silva, J., & Bustamante, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020486 · Cited by 4
“In the 2023 STEP-HFpEF trial, semaglutide (2.4 mg/week) improved exercise capacity (+21 m in the 6 min walk test) and reduced NT-proBNP levels by 15% in obese HFpEF patients, with effects attributed to decreased ROS and enhanced mitochondrial biogenesis via AMPK activation [127].”
InfluentialImpacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction
Isaacs, E., Idowu, A. B., Melo, M. H. S. T. D., Rembalsky, A., Wattanachayakul, P., & Pressman, G. S. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.022 · Cited by 3
Rosenzveig, A., Tefera, L. T., Agrawal, A., Rajendran, J., Massad, F., Badwan, O. Z., Wajsberg, J. R., Chaudhury, P., Zidar, D. A., Paul, T. K., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045664 · Cited by 2
Malik, F., Shah, M., Chang, Y. K., Chowdhury, I. Z., Mangalesh, S., Morgan, A. A., Ezerioha, P., Modak, V., Lebovics, N., Adhikari, S., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag044 · Cited by 2
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Borghi, C., & Bragagni, A. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag029 · Cited by 1
Precision Phenotyping of Heart Failure in People with HIV: Early Insights and Challenges
Grunblatt, E., & Feinstein, M. J. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00674-w · Cited by 1
“In the STEP-HFpEF trial, obese HFpEF patients treated with semaglutide experienced significant improvement in HF related symptoms and func - tional capacity, as well as a notable 43.5% decrease in levels of the inflammatory marker, C-reactive protein [104].”
InfluentialZhu, W., Peng, J., Yan, Z., Chen, Y., Xu, J., & Zhang, L. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1730457 · Cited by 2
Yang, M., Henderson, A. D., Anand, I. S., Desai, A. S., Lam, C. S. P., Maggioni, A. P., Martínez, F. A., Rouleau, J. L., Swedberg, K. B., Vaduganathan, M., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf064 · Cited by 1
Evaluating Noninferiority in Clinical Trials with a Hierarchical End Point
Gregson, J., Redfors, B., Cohen, D. J., et al. (2026) · NEJM Evidence · doi:10.1056/evidctw2500029 · Cited by 1
First study with positive cardiovascular outcome in obesity: Reflections on SELECT
Pan, Q., Fei, S., Xie, T., & Guo, L. (2024) · Aging Medicine · doi:10.1002/agm2.12300 · Cited by 1
“21 In previous studies involving patients with overweight or obesity, such as STEP-HFpEF (Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity) 22 and the STEP Programme, semaglutide 2.4 mg has been shown to reduce hsCRP levels by more than 50% compared to baseline.”
BackgroundMethodInfluentialLee, R. S. M., Seah, J., Baqar, S., Srivastava, P., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026) · Medicina · doi:10.3390/medicina62050870 · Cited by 2
“The STEP-HFpEF studies evaluated the usefulness of semaglutide (2.4 mg per week), whilst the SUMMIT trial used tirzepatide (up to 15 mg per week) in the above settings [24–26].”
InfluentialMayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Gewichtsreduktion mit Inkretinmimetika – Chancen und Risiken
Zech, T., Kirchweger, B., & Fürst, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01918-0
Obesity and the Obesity Paradox in Heart Failure
Koos, A., Vyas, A., Catalfamo, V. J., Tutor, A. W., & Lavie, C. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00177-1
Patel, J., Patel, D., & Pino, M. (2026) · Cureus · doi:10.7759/cureus.112239
“In both STEP-HFpEF and STEP-HFpEF DM trials, semaglutide led to a significantly greater improvement in KCCQ-CSS from baseline to 52 weeks than placebo [9,10].”
InfluentialObesitas a kardiovaszkuláris prevenció szemszögéből
Simonyi, G. (2024) · Cardiologia Hungarica · doi:10.26430/chungarica.2024.54.1.39 · Cited by 1
Sleep-Disordered Breathing in Heart Failure: Phenotypes, Mechanisms, and Precision Approach
Yi, H., Drager, L. F., Wang, X., Kasai, T., & Lee, C. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.06.021
Allen, L. A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.02.010
Win statistics applied to registry-based randomized clinical trials
Rylance, R. T., Wagner, P., Götberg, M., et al. (2026) · Trials · doi:10.1186/s13063-026-09598-3
“Otherwise, if the number of ties is negligible like in the Semaglutide in patients with heart failure with pre-served ejection fraction and obesity trial with only 5.1% ties, the stratified WR is 1.72 (1.37–2.15) and reflects nearly the entire population [27].”
InfluentialPharmacotherapy (Obesity Management Medications)
Blacklock, R. M., Lim, A. Y. L., Koh, H., Miras, A. D., & Brown, A. C. (2026) · Wiley eBooks · doi:10.1002/9781394206148.mdp0070
Chen, L., Wang, Q., Shen, M., Li, M., Zhu, Y., Zheng, C., Ma, S., Lin, H., Fu, X., Zhang, R., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70090
Systemerkrankung Herzinsuffizienz
Christa, M., & Maack, C. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00677-w
Heart Failure in 2025: Update With Perioperative Considerations
Mendapara, P., Ramakrishna, H., & Stawiarski, K. M. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.08.019 · Cited by 1
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
Thirugnanam, A. M., Chandrakanth, & Pruthvi (2026) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2026.03.011
Incretin analogues as cardiovascular agents: a state-of-the-art review
Garaygordobil, D. A., Rico-Fontalvo, J. E., Hernández-Balbuena, B., Vinay, M., & Gonzalez-Arias, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898812 · Cited by 1
“%) is one of the largest reported with any cardiometabolic drug class, and it correlates only loosely with weight loss (9, 14, 28).”
InfluentialChen, P., Yin, X., Liu, B., & Ren, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1821564
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Guo, J., & Chen, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933018
“STEP-HFpEF demonstrated that semaglutide 2.4 mg improves symptoms, functional capacity, and quality of life in this population (Kosiborod et al., 2023).”
InfluentialThe Family Physician’s Unique Role in Heart Failure Management
Chua, G. L. (2024) · Canadian Primary Care Today · doi:10.58931/cpct.2024.2335
Eyadiel, L., & Modarressi, T. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.08.015
Therapeutic Approach to Heart Failure Management: Insight from Clinical Trials
Kumar, A., Fowler, R., Ruggerio, E., Monahan, J., Battle, S. J., Ampadu, J. O., DiPette, D. J., & Potts, J. D. (2026) · Southern Medical Journal · doi:10.14423/smj.0000000000001965
ONE PATHWAY, INFINITE POTENTIAL? THE FUTURE OF GLP-1 THERAPIES: A 2026 CLINICAL UPDATE
Fidelis, M., Wojcieszek, M., Gondek, K., Gacka, D., Zalewska, A., Mączyńska, A., Al-karawi, N. A., Kędziorek, P., & Tanç, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4980
The Role of GLP-1R and GIPR Agonism in Heart Failure
Sedrak, P., & Connelly, K. A. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3138 · Cited by 1
Zidek, W. (2025) · Diabetes aktuell · doi:10.1055/a-2624-1018
“Herzin-suffizienz mit erhaltener Ejektionsfraktion [6, 7].”
Toole, J., Bae, S., Wutawunashe, C. V., Kim, M. C., & Kodra, A. (2026) · International Journal of Angiology · doi:10.1055/a-2874-9189
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644 · Cited by 1
“Third, observational studies and pharmacoepidemiologic analyses have reported associations between GLP-1 receptor agonist use and reduced incidence of diverse conditions including Alzheimer’s disease, alcohol use disorder, and certain malignancies [18–20].”
Adipose Tissue Dysfunction: Clinical Implications and Complications
Dronkers, J., Lobeek, M., Meems, L. M. G., & Gorter, T. M. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-72570-8_5
Heart Failure with Reduced and Preserved Ejection Fraction
Eyadiel, L. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2024.11.002
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
“…trials showed clinically meaningful improvements in symptoms, exercise tolerance, and quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ); it was also associated with significant weight loss and reductions in NT-proBNP and inflammation (C-reactive protein) [21,22].”
Skeletal Muscle Dysfunction in Heart Failure
Challa, A. A., Pandey, A., Brubaker, P. H., Kitzman, D. W., Bozkurt, B., & Kalra, D. K. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103353
Self-citationThe Cost of Inaction in Treating Obesity in the U.S.
Sapra, T., Chen, F., Dall, T. M., Hafida, S., Moody, A., Ferguson, C., Livingston, T., ElSayed, N. A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0011
Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related MorbiditiesPreprint
Kim, M., Chen, Q.-L., Sui, Y., Yang, X., Wang, S.-Q., Weng, L.-C., Cho, S. M. J., Koyama, S., Zhu, X., Yu, K., et al. (2024) · medRxiv · doi:10.1101/2024.11.01.24316620 · Cited by 3
“31,32 Despite its growing status as a widely used treatment, the challenges in the pharmacological intervention lie in evaluating the risk-benefit ratio for each individual, as GLP-1 receptor agonists are not without adverse effects.”
The Role of GLP 1 Receptor Agonists in Treating Heart Failure: Useful or Not?
Lungeanu, L., Nica, A., Rusu, E., & Radulian, G. (2024) · Internal Medicine · doi:10.2478/inmed-2024-0276
Update: Herzinsuffizienz mit erhaltener Pumpfunktion
Morbach, C., & Störk, S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2096-7448
“…sich in der rezent publizierten STEP-HFpEF-Studie, die bei 529 Patienten mit HFpEF eine signifikante Abnahme des Körper-gewichts unter Semaglutid zeigte, verbunden mit einer signifikanten Verbesserung der Lebensqualität und der 6-Minuten-Gehstrecke sowie einer Abnahme des C-reak-tiven Proteins [6].”
BackgroundA Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Reframing the Cytokine Hypothesis: Lessons Learned From Clonal Hematopoiesis
Mann, D. L. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013941 · Cited by 1
Which heart failure phenotypes benefit from GLP-1 receptor agonists?
Deng, J. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00328-x
“Dedicated randomized trials have demonstrated favorable effects of semaglu-tide in carefully selected patients with obesity-associated HFpEF [6], and similar benefits have also been observed in individuals with obesity-related HFpEF and type 2 diabetes [7].”
Rapport 24-09. Changement de paradigme dans les maladies cardio-néphro-métaboliques
Reach, G., & Jaffiol, C. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.10.002 · Cited by 2
Cardiovascular–Kidney–Metabolic Syndrome: Models of Care
Chung, I., Fricska, D. I., Banerjee, S., Banerjee, P., Gomez-Johnson, V. H., Annear, N. M. P., Chaudhury, A. R., Chen, M., Anderson, L., & Banerjee, D. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm47862 · Cited by 1
“…randomized controlled trials have identified therapies that confer benefits across all three systems, such as sodium–glucose co-transporter 2 (SGLT-2) inhibitors [13], glucagon-like peptide-1 (GLP-1) agonists [14], and non-steroidal mineralocorticoid receptor inhibitors [15].”
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Veloso, J. S., Corrêa, L. B., de Vasconcelos, L. R. R. A., Guimarães, A. C. S., & Dantas, R. A. E. (2025) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2025v7n6p927-945 · Cited by 1
Semaglutid gir både vekttap og mindre hjertesviktsymptomer
Benestad, H. B. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0682
Managing patients with heart failure: A contemporary practice tool for pharmacists
Barry, A. R., & Koshman, S. L. (2026) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3138/cpj-25-0119
Diet, Nutrition, and Managing Obesity
Salberg, L. R., & Turer, A. T. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_17
Cheng, X., Ma, R., Guo, M., Wei, J., Zhao, Q., Yu, R. E., Dong, Z., Wang, J., Wang, Y., 朱明军, et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1902637
Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies
Erhabor, J., Silver, N., & Blaha, M. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.024
Oral semaglutide in HFpEF: Real-world evidence and causal considerations
Catalán, V., Frühbeck, G., & Gómez‐Ambrosi, J. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.024
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
“Semaglutide Treatment Effect in People With Obesity and Heart Failure With Preserved Ejection Fraction (STEP-HFpEF) provided phenotype-specific evidence, with semaglutide improving HF symptoms, physical limitations, exercise function, and body weight in patients with HFpEF and obesity ( 14).”
Sun, X., Tang, X., Jin, M., Yuan, W., & Yuan, G. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1901876
Shah, S., Abusafia, M., Sheashaa, H., Jadam, S., Ospina, S., Kaelber, D. C., Keen, S., Cho, L., & Desai, M. Y. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.09.016
Self-citation
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.